Novo Nordisk B

FDA warning hits Novo Nordisk, but a new Hims & Hers partnership could drive $1.2 B in U.S. telehealth sales while offsetting looming patent cliffs.

New Novo Nordisk‑Hims & Hers deal expands Ozempic and Wegovy access via telehealth, boosting weight‑loss treatment reach while maintaining safety and efficacy standards.

Discover how Novo Nordisk’s partnership with Hims & Hers reshapes GLP‑1 sales, boosts revenue and strengthens its competitive edge in digital health.

Discover how Novo Nordisk’s new partnership with Hims & Hers could reshape obesity treatment, boost market reach, and raise regulatory and brand‑management questions.

Novo Nordisk partners with Hims & Hers to deliver obesity drugs via digital health, boosting patient access, safety data, and cost‑effective care.

How Novo Nordisk’s GLP‑1 patent suit and FDA guidance boost share price, protect pricing power, and impact patient access and safety.

Novo Nordisk sues telehealth firm over counterfeit Ozempic, protecting IP, safety and market share while highlighting risks of unverified weight‑loss drugs.

Explore how Novo Nordisk’s latest earnings dip and new obesity drug launch influence stock, pricing, legal battles, and reimbursement dynamics.

How Novo Nordisk’s stock bounced back after a rival’s low‑cost weight‑loss pill was halted by the FDA, and why Wegovy remains the top GLP‑1 choice for patients.

How Novo Nordisk’s stock fell after a low‑cost competitor released an oral weight‑loss drug, and what it means for pricing, reimbursement and future obesity therapy.